Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1981 Nov;12(5):621–629. doi: 10.1111/j.1365-2125.1981.tb01280.x

Pharmacokinetics of the enantiomers of acenocoumarol in man.

J Godbillon, J Richard, A Gerardin, T Meinertz, W Kasper, E Jähnchen
PMCID: PMC1401957  PMID: 7332726

Abstract

1 The pharmacokinetics of R(+)-, S(-)- and R,S(+/-)-acenocoumarol were studied in healthy volunteers after administration of single oral and intravenous doses. 2 After both oral and i.v. administration of either enantiomer in a dose of 0.25 mg/kg, the concentrations of R(+) found in the plasma were much higher than those of S(-). This indicates that the observed differences are not related to stereoselective absorption. 3 After intravenous administration of 25 mg of each enantiomer and the racemate, the total plasma clearance of S(-) was about 10 times that of R(+). The clearance of the racemate was between that of the enantiomers. 4 The apparent elimination half-life of S(-) was much shorter than those of R(+) and the racemate, which were similar. 5 The apparent volume of distribution VdSS of S(-) acenocoumarol was 1.5 to 2 times that of R(+). 6 Measurements of the extent of binding to serum proteins, made in vitro at much higher concentrations than those observed in vivo, revealed no differences between the two enantiomers and the racemate. 7 The results indicate that the greater anticoagulant potency of R(+) compared with S(-) acenocoumarol can be explained mainly by stereoselective differences in their metabolic clearance.

Full text

PDF
629

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Breckenridge A., Orme M., Wesseling H., Lewis R. J., Gibbons R. Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin Pharmacol Ther. 1974 Apr;15(4):424–430. doi: 10.1002/cpt1974154424. [DOI] [PubMed] [Google Scholar]
  2. Brown N. A., Jähnchen E., Müller W. E., Wollert U. Optical studies on the mechanism of the interaction of the enantiomers of the antiocagulant drugs phenprocoumon and warfarin with human serum albumin. Mol Pharmacol. 1977 Jan;13(1):70–79. [PubMed] [Google Scholar]
  3. Dieterle W., Faigle J. W., Montigel C., Sulc M., Theobald W. Biotransformation and pharmacokinetics of acenocoumarol (Sintrom) in man. Eur J Clin Pharmacol. 1977;11(5):367–375. doi: 10.1007/BF00566534. [DOI] [PubMed] [Google Scholar]
  4. Hewick D. S., McEwen J. Plasma half-lives, plasma metabolites and anticoagulant efficacies of the enantiomers of warfarin in man. J Pharm Pharmacol. 1973 Jun;25(6):458–465. doi: 10.1111/j.2042-7158.1973.tb09133.x. [DOI] [PubMed] [Google Scholar]
  5. Hewick D. S., Shepherd A. M. The plasma elimination of the enantiomers of phenprocoumon in man. J Pharm Pharmacol. 1976 Mar;28(3):257–258. doi: 10.1111/j.2042-7158.1976.tb04145.x. [DOI] [PubMed] [Google Scholar]
  6. Hirtz J., Le Roux Y., Jaouen A., Richard J., Blatrix C., Thébault J. J., Schoeller J. P. Clinical pharmacology studies with acenocoumarol. Int J Clin Pharmacol Biopharm. 1979 Aug;17(8):361–365. [PubMed] [Google Scholar]
  7. Jähnchen E., Meinertz T., Gilfrich H. J., Groth U., Martini A. The enantiomers of phenprocoumon: pharmacodynamic and pharmacokinetic studies. Clin Pharmacol Ther. 1976 Sep;20(3):342–349. doi: 10.1002/cpt1976203342. [DOI] [PubMed] [Google Scholar]
  8. Kelly J. G., O'Malley K. Clinical pharmacokinetics of oral anticoagulants. Clin Pharmacokinet. 1979 Jan-Feb;4(1):1–15. doi: 10.2165/00003088-197904010-00001. [DOI] [PubMed] [Google Scholar]
  9. Le Roux Y., Richard J. Determination of acenocoumarol in plasma and urine by double radioisotope derivative analysis. J Pharm Sci. 1977 Jul;66(7):997–1000. doi: 10.1002/jps.2600660725. [DOI] [PubMed] [Google Scholar]
  10. Levy G., O'Reilly R. A., Wingard L. B., Jr Comparative pharmacokinetics of coumarin anticoagulants XXXV: Examination of possible pharmacokinetic interaction between (R)-(+)- and (S)-(--)-warfarin in humans. J Pharm Sci. 1978 Jun;67(6):867–868. doi: 10.1002/jps.2600670640. [DOI] [PubMed] [Google Scholar]
  11. Levy G., O'Reilly R. A., Wingard L. B., Jr Relationship between the kinetics of the anticoagulant effects of racemic warfarin and its individual enantiomers in man. Res Commun Chem Pathol Pharmacol. 1974 Feb;7(2):359–365. [PubMed] [Google Scholar]
  12. Lewis R. J., Trager W. F., Chan K. K., Breckenridge A., Orme M., Roland M., Schary W. Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone. J Clin Invest. 1974 Jun;53(6):1607–1617. doi: 10.1172/JCI107711. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Lewis R. J., Trager W. F., Robinson A. J., Chan K. K. Warfarin metabolites: the anticoagulant activity and pharmacology of warfarin alcohols. J Lab Clin Med. 1973 Jun;81(6):925–931. [PubMed] [Google Scholar]
  14. Meinertz T., Kasper W., Kahl C., Jähnchen E. Anticoagulant activity of the enantiomers of acenocoumarol. Br J Clin Pharmacol. 1978 Feb;5(2):187–188. doi: 10.1111/j.1365-2125.1978.tb01622.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. O'Reilly R. A. Interaction of several coumarin compounds with human and canine plasma albumin. Mol Pharmacol. 1971 Mar;7(2):209–218. [PubMed] [Google Scholar]
  16. O'Reilly R. A. Studies on the optical enantiomorphs of warfarin in man. Clin Pharmacol Ther. 1974 Aug;16(2):348–354. doi: 10.1002/cpt1974162348. [DOI] [PubMed] [Google Scholar]
  17. Wheeler C. R., Trager W. F. Absolute configuration of acenocoumarin. J Med Chem. 1979 Sep;22(9):1122–1124. doi: 10.1021/jm00195a023. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES